[Management of erectile dysfunction in the cardiac patient]

Dtsch Med Wochenschr. 2005 Dec 16;130(50):2899-903. doi: 10.1055/s-2005-923324.

[Article in German]

Authors

C Gratzke¹, A J Becker, J-W Park, O Reich, E Waldkirch, B Schlenker, C G Stief

Affiliation

¹ Urologische Klinik und Poliklinik der LMU München. [email protected]

PMID: 16342015
DOI: 10.1055/s-2005-923324

No abstract available

MeSH terms

3',5'-Cyclic-GMP Phosphodiesterases
Cause of Death
Coronary Disease / complications*
Coronary Disease / diagnosis
Coronary Disease / drug therapy
Cyclic Nucleotide Phosphodiesterases, Type 5
Energy Metabolism / physiology
Humans
Impotence, Vasculogenic / diagnosis
Impotence, Vasculogenic / drug therapy
Impotence, Vasculogenic / etiology*
Male
Myocardial Infarction / complications
Myocardial Infarction / diagnosis
Myocardial Infarction / drug therapy
Myocardial Infarction / mortality
Patient Education as Topic
Phosphodiesterase Inhibitors / therapeutic use
Phosphoric Diester Hydrolases / drug effects
Physical Examination
Risk Factors

Substances

Phosphodiesterase Inhibitors
Phosphoric Diester Hydrolases
3',5'-Cyclic-GMP Phosphodiesterases
Cyclic Nucleotide Phosphodiesterases, Type 5
PDE5A protein, human